Researchers said it was the first analysis "measuring the treatment burden of checkpoint inhibitor therapy for early-stage breast cancer.
Researchers said it was the first analysis "measuring the treatment burden of checkpoint inhibitor therapy for early-stage breast cancer.
Physicians commonly underrecognized adverse events that breast cancer patients experienced after radiotherapy.